

1 **Alternative splicing in the lung influences COVID-19 severity and respiratory diseases.**

2
3 Tomoko Nakanishi¹⁻⁴; Yossi Farjoun²; Julian Willett^{2,5,6}; Richard J. Allen⁷, Beatriz Guillen-Guio⁷, Sirui
4 Zhou^{1,5,6}; J. Brent Richards^{1,2,8-10}

5
6 **Affiliations:**

- 7 1. Department of Human Genetics, McGill University, Montréal, Québec, Canada.
- 8 2. Centre for Clinical Epidemiology, Department of Medicine, Lady Davis Institute, Jewish General
9 Hospital, McGill University, Montréal, Québec, Canada.
- 10 3. Kyoto-McGill International Collaborative Program in Genomic Medicine, Graduate School of
11 Medicine, Kyoto University, Kyoto, Japan.
- 12 4. Research Fellow, Japan Society for the Promotion of Science, Tokyo, Japan.
- 13 5. Quantitative Life Sciences Program, McGill University, Montréal, Canada.
- 14 6. McGill Genome Centre, McGill University, Montréal, Québec, Canada.
- 15 7. Department of Health Sciences, University of Leicester, Leicester, United Kingdom.
- 16 8. Department of Epidemiology, Biostatistics and Occupational Health, McGill University,
17 Montréal, Québec, Canada.
- 18 9. Department of Twin Research, King's College London, London, United Kingdom.
- 19 10. 5 Prime Sciences Inc, Montréal, Québec, Canada.

20
21 **Corresponding author:**

22 J. Brent Richards
23 Professor of Medicine, McGill University
24 Senior Lecturer, King's College London (Honorary)
25 Pavilion H-413, Jewish General Hospital
26 3755 Côte-Ste-Catherine Montréal, Québec, Canada, H3T 1E2
27 T: +1 514 340 8222 x24362 F: +1 514 340 7529
28 E: brent.richards@mcgill.ca www.mcgill.ca/genepi

29
30 **Key words:** Genome-wide association studies, COVID-19, Mendelian randomization, alternative splicing

31
32

33 **Abstract**

34 Hospital admission for COVID-19 remains common despite the successful development of vaccines
35 and treatments. Thus, there is an ongoing need to identify targets for new COVID-19 therapies.
36 Alternative splicing is an essential mechanism for generating functional diversity in protein isoforms
37 and influences immune response to infection. However, the causal role of alternative splicing in
38 COVID-19 severity and its potential therapeutic relevance is not fully understood. In this study, we
39 evaluated the causal role of alternative splicing in COVID-19 severity and susceptibility using
40 Mendelian randomization (MR). To do so, we performed two-sample MR to assess whether *cis*-sQTLs
41 spanning 8,172 gene splicing in 5,295 genes were associated with COVID-19 outcomes in the
42 COVID-19 Host Genetics Initiative, including up to 158,840 COVID-19 cases and 2,782,977
43 population controls. We identified that alternative splicing in lungs, rather than total RNA expression of
44 *OAS1*, *ATP11A*, *DPP9* and *NPNT*, was associated with COVID-19 severity. *MUC1* splicing was
45 associated with COVID-19 susceptibility. Further colocalization analyses supported a shared genetic
46 mechanism between COVID-19 severity with idiopathic pulmonary fibrosis at *ATP11A* and *DPP9* loci,
47 and with chronic obstructive lung diseases at *NPNT*. We lastly showed that *ATP11A*, *DPP9*, *NPNT*,
48 and *MUC1* were highly expressed in lung alveolar epithelial cells, both in COVID-19 uninfected and
49 infected samples. Taken together, these findings clarify the importance of alternative splicing of
50 proteins in the lung for COVID-19 and other respiratory diseases, providing isoform-based targets for
51 drug discovery.

52

53

54 Introduction

55 Despite the successful development of vaccines^{1,2} and treatments^{3,4}, hospital admission for severe
56 COVID-19 and long-term sequela for COVID-19 remain common^{5,6}. COVID-19 is now a leading cause
57 of death, accounting for 350,000 deaths⁷ and the estimated COVID-19 mortality rate is generally higher
58 than that of influenza by 2 to 100-fold, which vary by the study design^{7,8}. Thus, there is an ongoing need
59 to identify mechanistic targets for therapeutic development to reduce the risk of severe COVID-19.

60
61 Using human genetics methods, several host factors have been identified to influence COVID-19
62 severity, including *OAS1*, type I interferon and chemokine genes⁹⁻¹⁴. Human genetics can provide new
63 biological insights into disease pathogenesis and the therapeutic targets and evidence from human
64 genetics increases the probability of drug development success^{15,16}. While prior studies have evaluated
65 causal roles of both RNA expression and circulating proteins in COVID-19 outcomes^{9,12,13}, the causal
66 role of alternative splicing has not been fully investigated.

67
68 Alternative splicing is an essential mechanism for generating functional diversity in the isoforms, through
69 which multiple mRNA isoforms are produced from a single gene, often in tissue-specific patterns¹⁷.
70 Alternative splicing has been implicated to play an important role in immune response to infections in
71 humans¹⁷, and this might be the case for SARS-CoV-2 infection. The genetic determinants of alternative
72 splicing have been identified using splicing quantitative trait loci (sQTL) studies, which indicate that
73 splicing is under strong genetic control in humans and often has direct effects on protein isoforms.
74 Indeed, we have recently identified that a Neanderthal-interrogated isoform of *OAS1*, which is strongly
75 regulated by an sQTL, affords protection against COVID-19 severity⁹. Given this evidence, we
76 hypothesized that alternative splicing could partially explain the variability in COVID-19 outcomes in
77 humans.

78

79 In this study, to test our hypothesis, we undertook two-sample MR and colocalization analyses to
80 combine results from genome-wide association studies (GWASs) of gene splicing and COVID-19
81 outcomes¹⁸. To do so, we first obtained the *cis*-regulatory genetic determinants of gene splicing (*cis*-
82 sQTLs) in lungs and whole blood, two relevant tissues that influence acute SARS-CoV-2 infection, from
83 the GTEx Consortium¹⁹. We then used MR to assess whether these gene splicing events have effects on
84 COVID-19 outcomes using the GWASs from the COVID-19 Host Genetics Initiative¹¹. Next, all findings
85 were assessed for colocalization to ensure that the gene splicing and COVID-19 outcomes shared a
86 common etiological genetic signal and that the MR results were not biased by linkage disequilibrium
87 (LD). We also compared effects of alternative splicing to total RNA expression and evaluated the
88 expression in the lung transcriptome datasets. Finally, we evaluated whether such alternative splicing is
89 a shared pathophysiological mechanism with other respiratory diseases.

90

91

92 **Results**

93 ***MR using cis-sQTLs, and colocalization analyses***

94 The study design is illustrated in **Fig. 1**. We obtained the genetic determinants of gene splicing
95 (splicing quantitative trait locus [sQTL]) that influence alternative splicing events, which were
96 quantified as normalized intron excision ratios, *i.e.* the proportion of reads supporting each
97 alternatively excised intron, by LeafCutter²⁰ (using a multiple-testing correction threshold of a false
98 discovery rate of 5% per tissue) in GTEx v.8¹⁹. We chose to examine only *cis*-sQTLs, which act *cis* to
99 the coding genes, as it is less likely that these act through horizontal pleiotropy, where the SNPs have
100 effects on diseases (here, COVID-19 outcomes) independently of the gene splicing. We also focused
101 on two COVID-19-relevant tissues; lungs (N=515, of which 452 were of European American ancestry)
102 and whole blood (N=670, of which 570 were of European American ancestry) since pulmonary
103 symptoms are the major determinant of hospital admission and the immune system plays a major role
104 in host response to SARS-CoV-2.

105
106 A total of 4,477 genes in lungs and 2,779 genes in whole blood (5,295 unique genes in total) contained
107 conditionally independent *cis*-sQTLs that were also present the GWAS meta-analyses of COVID-19 Host
108 Genetics Initiative¹¹ release 7 (<https://www.covid19hg.org/results/r7/>), which included results from the
109 GenOMICC¹² study. We then undertook two-sample MR analyses using 6,110 *cis*-sQTLs in lungs and
110 3,883 *cis*-sQTLs in whole blood as genetic instruments for gene splicing for three COVID-19 outcomes:
111 1) critical illness (defined as individuals experiencing death, mechanical ventilation, non-invasive
112 ventilation, high-flow oxygen, or use of extracorporeal membrane oxygenation) owing to symptoms
113 associated with laboratory-confirmed SARS-CoV-2 infection (18,152 cases and 1,145,546 controls, of
114 which 13,769 and 1,072,442 were of European ancestry); 2) hospitalization owing to symptoms
115 associated with laboratory-confirmed SARS-CoV-2 infection (44,986 cases and 2,356,386 controls, of
116 which 32,519 and 2,062,805 were of European ancestry); and 3) reported SARS-CoV-2 infection defined
117 as laboratory-confirmed SARS-CoV-2 infection, electronic health record or clinically confirmed COVID-
118 19, or self-reported COVID-19, with or without symptoms of severity (159,840 cases and 2,782,977
119 controls, of which 122,616 and 2,475,240 are of European ancestry). Our primary MR analyses used
120 data from individuals of all ancestries, so as not to discard data for minority populations²¹, albeit the vast
121 majority of the individuals were of European ancestry; 86.2% in GTEx and 88.8% in COVID-19 HGI). We
122 also performed MR analyses using data derived only from European population as described below.
123
124 MR analyses identified 29 genes, whose alternative splicing in lung influenced COVID-19 outcomes.
125 Using whole blood-derived alternative splicing we identified 20 genes influencing the same outcomes.
126 All associations survived a p-value threshold of 5.1×10^{-6} , which was based on Bonferroni correction
127 using the number of splicing events tested (in total 8,172 [5,999 in lung and 3,769 in whole blood],
128 **Methods, Supplementary Table 1,2**). We first replicated the association of COVID-19 outcomes with
129 *OAS1* gene splicing which increases the excision of the intron junction at chr12:112,917,700-
130 112,919,389 [GRCh38] both in lung and whole blood, that corresponds to an increased level of the

131 p46 isoform, a prenylated form of OAS1 with higher anti-viral activity than the p42 isoform²²⁻²⁴ (**Fig. 2,**
132 **Extended Data Fig. 1A, Supplementary Table 1,2).**

133

134 We additionally identified that *ATP11A* sQTL, rs12585036:T>C, which increases the excision of the
135 intron junction at chr13:112,875,941-112,880,546 in lung, was associated with protection against all
136 three adverse COVID-19 outcomes with odds ratio [OR] per normalized intron excision ratio [the
137 proportion of reads supporting each alternatively excised intron identified by LeafCutter²⁰] of 0.78
138 (95%CI: 0.73-0.82, p=9.3x10⁻¹⁹) for critical illness, OR of 0.84 (95%CI: 0.81-0.87, p=3.1x10⁻²¹) for
139 hospitalization, and OR of 0.96 (0.94-0.97, p=2.9x10⁻⁶) for reported infection (**Fig. 2, Extended Data**
140 **Fig. 1B, Supplementary Table 1).**

141

142 We also found novel associations of *DPP9* sQTL, rs12610495:G>A, which increases the excision of
143 the intron junction at chr19:4,714,337-4,717,615 in lung, with protection against all three adverse
144 COVID-19 outcomes (OR: 0.49, 0.45-0.54, p=5.5x10⁻⁵⁹ for critical illness, OR: 0.64, 0.61-0.68,
145 p=4.0x10⁻⁵² for hospitalization, and OR: 0.85, 0.83-0.88, p=3.2x10⁻²⁹ for reported infection, **Fig. 2).**

146 *DPP9* has two major isoforms, DPP9L (longer isoform, 863 aa, ENST00000262960) and DPP9S
147 (shorter isoform, 863 aa, ENST00000598800)²⁵, and they differ in the presence of the skipping of exon
148 9 (chr19:4,715,529-4,716,152), which overlaps the intron junction at chr19:4,714,337-4,717,615
149 (**Extended Data Fig. 1C, Supplementary Table 1).**

150

151 *NPNT* rs34712979:A>G, which increases the intron junction of chr4:105,898,001-105,927,336
152 (**Extended Data Fig. 1D),** was associated with increased risk of severe COVID-19 outcomes (critical
153 illness and hospitalization) but with marginal evidence of increased risk of SARS-CoV-2 infection (OR:
154 1.18, 1.12-1.24, p=5.5x10⁻¹⁰ for critical illness, OR: 1.10, 1.07-1.14, p=3.8x10⁻⁸ for hospitalization, and
155 OR: 1.02, 1.00-1.03, p=4.2x10⁻² for reported infection, **Fig. 2, Supplementary Table 1).** The *NPNT*

156 sQTL, rs34712979-A allele, creates a NAGNAG splice acceptor site, which results in additional in-
157 frame AGT codon, coding for serine, at the 5' splice site of exon 2²⁶.
158
159 Gene splicing in the two genes in the gene cluster located in chr1 q21.3-q22, namely *MUC1* and
160 *THBS3*, in lung were also associated with reported SARS-CoV-2 infection, but not with COVID-19
161 severity phenotypes (**Fig. 2, Supplementary Table 1**). Given that the *MUC1* and *THBS3* sQTL SNPs
162 are in high LD with each other (rs4072037:C>T and rs2066981:A>G; $r^2=0.98$ in European population
163 of 1000G), it was challenging to distinguish which genes were more likely to be causal between *MUC1*
164 and *THBS3*. Nevertheless, *MUC1* sQTL SNP, rs4072037:C>T, is a recognized splice variant which
165 influences the 3' splice site selection of exon2²⁷. In GTEx, the rs4072037-T allele was associated with
166 decreased levels of the intron junction of chr1:155,192,310:155,192,786 (**Extended Data Fig. 1E**),
167 which leads to transcripts that have an alternative 27 bp intron retention event at the start of exon 2²⁷.
168 We demonstrated the rs4072037-C allele, which increases the levels of the intron junction of
169 chr1:155,192,310:155,192,786, was associated with increased risk of reported SARS-CoV-2 infection.
170 Given the well-known evidence of the splicing event of *MUC1*, it is more likely that *MUC1* gene
171 splicing has an impact of SARS-CoV-2 infection.
172
173 All of the above associations of gene splicing, except for *MUC1*, were more pronounced with more
174 severe outcomes (**Fig. 2**). We also applied MR for another hospitalization phenotype compared within
175 COVID-19 cases ("hospitalization vs non-hospitalization amongst individuals with laboratory-confirmed
176 SARS-CoV-2 infection", which corresponds to B1 phenotype in COVID-19 HGI¹¹). We confirmed the
177 associations with gene splicing in *ATP11A* and *DPP9* (*ATP11A*: OR 0.87, 0.81-0.94, $p=4.6 \times 10^{-4}$, and
178 *DPP9*: OR 0.83, 0.73-0.94, $p=4.9 \times 10^{-3}$) but not with gene splicing in *NPNT* and *OAS1*
179 (**Supplementary Table 3**).
180
181

182 **Colocalization and European-only MR analyses**

183 To test whether confounding due to linkage disequilibrium may have influenced the MR estimates, we
184 tested the probability that alternative splicing and the COVID-19 outcomes shared a single causal
185 signal using colocalization analyses, as implemented in coloc²⁸. These colocalization analyses were
186 performed using data from individuals of European ancestry, as this method assumes that the two
187 GWASs tested were derived from the individuals with the similar LD structure. We next performed MR
188 as a sensitivity analysis by using the data only from individuals of European descent to ensure that the
189 MR results were not biased from population stratification²⁹.

190
191 Amongst the MR-prioritized splicing events (29 genes in lung and 20 genes in whole blood,
192 **Supplementary Table 1,2**), we selected the splicing events with high (>0.8) posterior probability for
193 hypothesis 4 (PP, that there is an association for both gene expression/splicing and COVID-19
194 outcomes, which is driven by the same causal variant), and with a support from European-descent
195 only MR analysis ($p < 5.1 \times 10^{-6}$, where the p-value threshold was adopted from the main analysis) (**Fig1,**
196 **3, Extended Data Fig. 1**). These analyses retained 8 genes (*ABO*, *ATP11A*, *DPP9*, *GBAP1*, *MUC1*,
197 *NPNT*, *OAS1*, *THBS3*) whose alternative splicing in lung influenced at least one COVID-19 outcome
198 and 2 genes (*MOSPD3*, *OAS1*) whose alternative splicing in whole blood influenced at least one
199 COVID-19 outcome (**Supplementary Table 4,5**).

200
201 A posterior probability (PP) that alternative splicing of *ATP11A* in lungs and COVID-19 outcomes
202 shared a single causal signal in the 1Mb locus around the *cis*-sQTL was 1.00 for critical illness, 1.00
203 for hospitalization due to COVID-19, and 0.98 for reported infection (**Fig. 3A**). Alternative splicing of
204 *DPP9* had as high PP as 0.96 for critical illness, 0.96 for hospitalization, and 0.95 for reported infection
205 (**Fig. 3B**). Alternative splicing of *NPNT* had as high PP as 1.00 for critical illness, and 1.00 for

206 hospitalization, but had as low PP as 0.02 for reported infection (**Fig. 3C**). All of these gene splicing
207 had a support from European-descent only MR analysis with similar effect estimates as the main
208 analyses ($p < 5.1 \times 10^{-6}$, **Supplementary Table 4,5**).

209

210

211 *Colocalization with eQTL GWASs from GTEx*

212 Next, to understand if total gene expression levels in lung and whole blood were associated with
213 COVID-19 outcomes, without respect to the splicing or isoforms, we performed MR and colocalization
214 analyses using expression quantitative trait loci (eQTLs) in lung and whole blood from GTEx. The total
215 expression of *GBAP1* had MR evidence with reported SARS-CoV-2 infection ($p = 5.9 \times 10^{-8}$) and the
216 eQTLs of *ABO*, *GBAP1*, and *MOSPD3*, had high colocalization with COVID-19 outcomes (PP > 0.8,
217 **Supplementary Table 6, 7**). Thus, for those genes, we could not clarify whether the associations with
218 COVID-19 outcomes were driven by either total gene expression or the spliced isoform expression or
219 both.

220

221

222 *Influence of prioritized sQTLs on other diseases.*

223 We next searched for the effects of the sQTLs, which influence COVID-19 outcomes, on other
224 diseases. To do so, we used the Open Targets Genetics^{30,31} (<https://genetics.opentargets.org>) and
225 identified GWAS lead variants that were in LD ($r^2 > 0.80$) with COVID-19 associated sQTLs. We found
226 that the *DPP9* sQTL (rs12610495:G>A) was associated with decreased risk of idiopathic pulmonary
227 fibrosis (IPF)³² and the same allele confers the protection against COVID-19 severity. Interestingly, we
228 found the opposite direction of effects between IPF and COVID-19 in the sQTL for *ATP11A*, where the
229 rs12585036-C allele was associated with increasing risk of IPF and decreased risk for COVID-19

230 severity. The *NPNT* sQTL had similar trend that rs34712979-A allele, which was protective for COVID-
231 19 severity, was associated with increased risk of COPD (*i.e.* lower FEV1/FVC ratio, a spirometry
232 measurement used to diagnose COPD)^{33,34} and with increased risk of asthma³⁵. The *OAS1* sQTL
233 (rs10774671:A>G) was associated with a decreased risk of systemic lupus erythematosus (in the East
234 Asian population)³⁶ and with an increased risk of chronic lymphocytic leukemia³⁷. The *MUC1* sQTL
235 (rs4072037:T>C) was associated with decreased risk of gastric cancer³⁸, gout³⁹, and inflammatory
236 bowel disease⁴⁰.

237

238 We then performed colocalization analyses in each sQTL locus between COVID-19 outcomes and the
239 other associated diseases/phenotypes if the effects were supported in European population and there
240 was genome-wide GWAS summary data available. IPF³² and critical illness due to COVID-19 were
241 highly colocalized at the *ATP11A* and *DPP9* sQTL loci with PP of 1.00. The FEV1/FVC ratio also
242 colocalized with critical illness due to COVID-19 with a PP of 1.00. Inflammatory bowel disease⁴⁰ and
243 urate level (which is the cause of gout) also colocalized with reported SARS-CoV-2 infections at the
244 *MUC1* locus (both PPs are 1). We found no GWAS summary statistics available for the other diseases
245 (**Table 1**). These lines of evidence suggest that IPF and COVID-19 severity, COPD/asthma and
246 COVID-19 severity, and IBD and COVID-19 susceptibility may share causal genetic determinants in
247 these loci, respectively. The full results and the data used are summarized in **Table 1**.

248

249

250 *The tissue and cell-type specific expression of the associated genes*

251 To assess the relevant tissues and cell-types for the associated gene splicing – COVID-19 outcome
252 relationships, we evaluated the associated gene expression in lung and peripheral blood mononuclear
253 cell (PBMC) of healthy controls, as well as in lung of COVID-19 patients. In the consensus transcript
254 expression levels from Human Protein Atlas (HPA)⁴¹ and GTEx, the expression of *ATP11A*, and *NPNT*
255 were highly enriched in normal lung tissue (**Fig. 4A**). At a single-cell resolution, in normal lung, *MUC1*,

256 *ATP11A* and *NPNT* were specifically enriched in alveolar type 1 and 2 epithelial cells (**Fig. 4B**), which
257 are known to play important roles in regeneration of alveolar epithelium following lung injury⁴². In 23
258 lung COVID-19 autopsy donor tissue samples from GSE171668⁴³, the expression of *ATP11A*, *DPP9*,
259 *MUC1*, and *NPNT* were also enriched in alveolar type 1 and 2 epithelial cells (**Fig. 4C**). Taken
260 together, these expression evidence suggests that the gene splicing – COVID-19 outcome
261 relationships for *ATP11A*, *DPP9*, *MUC1*, and *NPNT* were highly likely to be relevant in lung tissue,
262 especially alveolar epithelial cells for *ATP11A*, *MUC1*, and *NPNT*.

263

264

265 Discussion

266 Despite current vaccines and therapeutic options, hospitalization for COVID-19 remains high in many
267 countries. Thus, there remains a need for additional therapies, which in turn, requires target
268 identification and validation⁴⁴. In this large-scale two-sample MR study of 8,172 gene splicing events
269 assessed for their effect upon three COVID-19 outcomes in up to 158,840 COVID-19 cases and
270 2,782,977 population controls, we provide evidence that alternative splicing of *OAS1*, *ATP11A*, *DPP9*
271 and *NPNT* in lung influences COVID-19 severity, and alternative splicing of *MUC1* in lung influences
272 COVID-19 susceptibility. Moreover, these genetic mechanisms are likely shared with other diseases,
273 such as *ATP11A* and *DPP9* with IPF, suggesting the potential to be targeted for multiple diseases.
274 Our results provide rationale to target gene splicing in lung as COVID-19 treatment by means of
275 therapeutic modalities such as splice-switching oligonucleotides (SSOs).

276

277 SSOs are a type of antisense oligonucleotides which are generally 15–30 nucleotides in length and
278 are designed as complementary to specific regions of mRNA with increased stability against
279 endogenous nucleases due to chemical modifications⁴⁵. SSOs can prevent splicing promoting factors
280 from binding to the target pre-mRNA, which can modulate alternative splicing⁴⁶. Some SSOs have
281 been already approved by FDA, such as eteplirsen for Duchenne’s muscular dystrophy, which induces

282 the skipping of exon 51 of *DMD* gene, and nusinersen for spinal muscle atrophy, which induces the
283 expression of exon 7 of *SMN2* gene⁴⁵. Although delivery to target tissues after systemic administration
284 has been a key challenge in the development of SSO drugs^{45,47}, lung might be advantageous tissue to
285 target since it is possible to deliver drugs directly to lung through inhalation and/or bronchoscopy.

286

287 There are multiple sources of biological evidence which might support the relevance of *ATP11A* in
288 COVID-19. *ATP11A* is a member of the P4-ATPase family, which codes for a phospholipid flippase at
289 the plasma membrane and translocates phosphatidylserine (PtdSer) from the outer to the inner leaflet
290 of plasma membranes. Cells that undergo apoptosis, necroptosis or pyroptosis expose PtdSer on their
291 surface through P4-ATPase, of which *ATP11A* is cleaved by caspase during apoptosis⁴⁸. While less
292 functionally defined, given the high expression of *ATP11A* in the alveolar type 2 epithelial cells,
293 *ATP11A* sQTL (rs12585036:C>T) may impact the cell death of alveolar type 2 epithelial cells, the
294 resident stem cell population in lung⁴⁹, and may impair regeneration of alveolar epithelium following
295 lung injury.

296

297 Our MR analysis showed that the excision of intron junction chr19:4,814,337-4,717,615, which may be
298 preferentially spliced in *DPP9L* than in *DPP9S*, was associated with reduced risk of COVID-19
299 severity. While both *DPP9L* and *DPP9S* can be active²⁵, *DPP9S* is present in the cytosol, and *DPP9L*
300 localizes preferentially to the nucleus, which may be attributed to a classical monopartite nuclear
301 localization signal (RKVKKLRL) in the N-terminal extension of *DPP9L*²⁵. Although it is not fully
302 understood how the *DPP9* sQTL (rs12610495:A>G) regulates alternative splicing of *DPP9*,
303 rs12610495-G allele creates a GGGG motif (from GGAG sequence), which may have an effect on
304 alternative splicing of some genes⁵⁰. *DPP9* interacts with NLRP1 and represses inflammasome
305 activation⁵¹ and pyroptosis, which are now recognized as important mechanisms interrupting the viral
306 replication cycle and preventing viral amplification of SARS-CoV-2⁵². Moreover, targeting

307 inflammasome-mediated hyperinflammation in COVID-19 patients may also prevent chronic phase of
308 COVID-19 pathophysiology in vivo⁵².

309

310 Our MR analyses supported that the *MUC1* gene splicing associated with susceptibility of SARS-CoV-
311 2 infection. *MUC1* is a mucin, which is also called KL-6 in human, and the serum level of KL-6 is used
312 as a biomarker for interstitial lung diseases⁵³. rs4072037-T allele was associated with the decreased
313 level of the intron junction of chr1:155,192,310:155,192,786, which corresponds to transcripts with an
314 alternative 27 bp intron retention event at the start of exon 2²⁷. *MUC1* exon 2 harbors a variable
315 number of tandem repeats (VNTR) that contains 20 to 125 repeats of a 60 bp coding sequence that
316 determines the length of a heavily glycosylated extracellular domain⁵⁴. Although rs4072037 may or
317 may not control the alternative splicing of VNTR region³⁸, in addition to the alternative 27 bp intron
318 retention²⁷, the VNTR length of *MUC1* is associated with several renal phenotypes in recent study in
319 UK Biobank⁵⁵. The rs4072037-T allele has been shown to be associated with increased risk of gastric
320 cancer in both European and East Asian ancestries^{38,56} and it is hypothesized that the *MUC1* gene is
321 involved in response to *H.pylori* colonization in gastric epithelial surfaces. Taken together, it is
322 plausible that alternative splicing of *MUC1* in lung alveolar cells has an impact on SARS-CoV-2
323 infection.

324

325 This study has limitations. First, the excised intron junction was quantified in an annotation-free
326 manner using LeafCutter²⁰, without respect to the level of transcripts nor isoforms. It is thus important
327 for future work to map those disease-relevant alternative splicing events to the corresponding isoform
328 or protein product, by means of emerging technologies such as long-read sequencing⁵⁷ and high-
329 throughput protein quantification⁵⁸. We anticipate our findings, and others, will motivate the ongoing
330 effort to do so. Second, we used MR to test the effect of gene splicing measured in a non-infected
331 state since the effect of the *cis*-sQTLs upon gene splicing was estimated in individuals who had not
332 been exposed to SARS-CoV-2. Given the dynamic gene regulation of splicing during infection⁵⁹, gene

333 splicing could be altered once a person experiences SARS-CoV-2 infection. Thus, the MR results
334 presented in this paper should be interpreted as an estimation of the effect of gene splicing during
335 uninfected state. Future studies may help to clarify if the same *cis*-sQTLs regulate alternative splicing
336 during infection. Third, it was not our goal to identify all alternative splicing that affects COVID-19
337 outcomes, but rather to provide strong evidence for a small set of genes with strong MR and
338 colocalization evidence. Thus, we acknowledge a high false-negative rate of our study design.
339 Although we attempted to include the data from individuals of diverse ancestries, most individuals
340 were of European descent. Therefore, we could not confirm that our findings could be robustly
341 transferrable to individuals of other populations. Fourth, while our findings demonstrate that effects of
342 alternative splicing in lung and whole blood since these are relevant to COVID-19 severity, we
343 recognize that these splicing events may not be unique to these tissues and thus the estimated effects
344 of splicing may represent the action of these same alternative transcripts in other tissues. Lastly, a
345 recent paper⁶⁰ reported that the shared genetic signal between IPF and COVID-19 outcomes at the
346 *DPP9* and *ATP11A* loci are likely driven by the difference of total expression in whole blood, which
347 was supported by colocalization using eQTLGen⁶¹ dataset. However, eQTLGen consists of multi-
348 ancestry cohorts and could be affected by the bias due to LD. Moreover, we demonstrated that both
349 *DPP9* and *ATP11A* expression were enriched in alveolar cells in lung, compared to whole blood.
350 Thus, we concluded that it is more likely that the alternative splicing of *DPP9* and *ATP11A* in lung is
351 important both for IPF and COVID-19 severity.

352
353 In conclusion, we have used genetic determinants of gene splicing and COVID-19 outcomes obtained
354 from large-scale studies and found compelling evidence that splicing events in *OAS1*, *ATP11A*, *DPP9*,
355 *NPNT*, and *MUC1* have causal effects on COVID-19 severity and susceptibility. Interestingly, the
356 available evidence suggests shared genetic mechanisms for COVID-19 severity with IPF at *ATP11A*
357 and *DPP9* loci, and with chronic obstructive lung diseases at the *NPNT* locus. Taken together, our

358 study highlights the importance of alternative splicing both in COVID-19 and other diseases, which
359 could be further investigated for drug discovery such as SSOs.

360

361

362 **Methods**

363 ***Splicing quantitative trait loci (sQTL) GWASs***

364 We obtained all conditionally independent splicing quantitative trait loci (sQTLs) in lung (N=515, of which
365 452 were of European ancestry) and whole blood (N=670, of which 570 were of European ancestry) that
366 act in *cis* (in a +/- 1Mb window around the transcription start site of each gene with normalized intron
367 excision ratios from LeafCutter²⁰ (5% FDR per tissue). Conditional independent sQTLs were mapped
368 using stepwise regression in GTEx consortium¹⁹. Intron excision ratios are the proportion of reads
369 supporting each alternatively excised intron identified by LeafCutter²⁰. We selected lung and whole blood
370 since they are the two major tissues relevant to COVID-19 pathophysiology.

371

372

373 ***COVID-19 GWASs***

374 To assess the association of *cis*-sQTLs with COVID-19 outcomes, we used COVID-19 GWAS meta-
375 analyses results from the COVID-19 Host Genetics Initiative (HGI) release 7¹¹
376 (<https://www.covid19hg.org/results/r7/>). The outcomes tested were critical illness, hospitalization, and
377 reported SARS-CoV-2 infection (named A2, B2, and C2, respectively by the COVID-19 HGI).

378

379 Critically ill COVID-19 cases were defined as those individuals who were hospitalized with laboratory-
380 confirmed SARS-CoV-2 infection and who required respiratory support (invasive ventilation, continuous
381 positive airway pressure, Bilevel Positive Airway Pressure, or continuous external negative pressure,
382 high-flow nasal or face-mask oxygen) or who died due to the disease. Simple supplementary oxygen
383 (e.g. 2 liters/minute via nasal cannula) did not qualify for case status. Hospitalized COVID-19 cases were

384 defined as individuals hospitalized with laboratory-confirmed SARS-CoV-2 infection (using the same
385 microbiology methods as for the critically ill phenotype), where hospitalization was due to COVID-19
386 related symptoms. Reported SARS-CoV-2 infection was defined as laboratory-confirmed SARS-CoV-2
387 infection or electronic health record, ICD coding or clinically confirmed COVID-19, or self-reported
388 COVID-19 (for example, by questionnaire), with or without symptoms of any severity. Controls were
389 defined in the same way across all three outcomes above as everybody that is not a case—for example,
390 population controls.

391
392 In a sensitivity analysis, we also used another hospitalization phenotype (named B1 in the COVID-19
393 HGI), where cases were hospitalized COVID-19 cases and controls were defined as non-hospitalized
394 individuals with laboratory-confirmed SARS-CoV-2 infection.

395
396
397 ***Two-sample Mendelian randomization***
398 We used two-sample mendelian randomization (MR) analyses using “TwoSampleMR v0.5.6” R
399 package⁶² to screen and test the potential role of alternative splicing in lung and whole blood to influence
400 COVID-19 outcomes. In two-sample MR, the effect of SNPs on the exposure and outcome are taken
401 from separate GWASs. Two-sample MR often improves statistical power and is less biased than one-
402 sample MR, with potential bias in the direction to the null⁶³. MR is less affected by confounding and
403 reverse causality than observational epidemiology studies. The MR framework is based on three main
404 assumptions: First, the SNPs are robustly associated with the exposure (*i.e.* a lack of weak instrument
405 bias). We validated that all *cis*-sQTLs had a F-statistic >10, corresponding to T-statistics >3.16, which
406 indicate a low risk of weak instrument bias in MR analyses⁶⁴. Second, the SNPs are not associated with
407 any confounding factors for the relationship between the exposure and the outcome. Third, the SNPs
408 have no effect on the outcome that is independent of the exposure (*i.e.* a lack of horizontal pleiotropy),
409 which is the most challenging assumption to assess. Nevertheless, in order to reduce the risk of

410 horizontal pleiotropy, we selected *cis*-sQTLs as instrumental variables, as *cis*-SNPs that reside close to
411 the genes are more likely to have an effect on the outcomes by directly influencing the splicing of the
412 gene. Palindromic *cis*-sQTLs with minor allele frequencies (MAF) >0.42 were removed prior to MR to
413 prevent allele-mismatches. For gene splicing with a single (sentinel) *cis*-sQTL, we used the Wald ratio to
414 estimate the effect of each splicing event on each of the three COVID-19 outcomes. For any gene
415 splicing event with multiple conditionally independent *cis*-sQTLs, an inverse variance weighted (IVW)
416 method was used to meta-analyze their combined effects. After harmonizing the *cis*-sQTLs with COVID-
417 19 GWASs, a total of 5,999 splicing events in 4,477 genes (6,110 matched *cis*-sQTLs) in lung and a total
418 of 3,769 splicing events in 2,779 genes (3,883 matched *cis*-sQTLs) in whole blood were used for the MR
419 analyses across the three COVID-19 outcomes. We applied the Bonferroni corrected p-value (5.1×10^{-6})
420 to adjust for multiple testing, by using the number of splicing events tested (5,999 in lung and 3,769 in
421 whole blood, in total 8,172).

422

423

424 ***European-only MR analyses and colocalization analysis***

425 Next, we assessed potential confounding by population stratification and linkage disequilibrium (LD). To
426 do so, we first repeated MR analyses using the data from individuals of European ancestry. We obtained
427 the effect estimate of each *cis*-sQTL from the data mapped in European-American subjects. If the *cis*-
428 sQTL was missing in the summary data mapped in European-ancestry subjects, we removed those *cis*-
429 sQTLs in the analyses. The three COVID-19 outcomes GWASs results were also replaced by the meta-
430 analyses summary results of European-ancestry subjects.

431

432 We also evaluated whether the gene splicing and COVID-19 outcomes shared a common etiological
433 genetic signal and that the MR results were not biased by linkage disequilibrium (LD) using colocalization
434 analyses with the data from individuals of European ancestry. Specifically, for each of these MR
435 significant splicing events, a stringent Bayesian analysis was implemented in “coloc v 5.1.0.1” R package

436 to analyze all variants in 1MB genomic locus centered on the *cis*-sQTL. Colocalizations with posterior
437 probability for high colocalization (PP >0.8), that is, that there is an association for both gene splicing and
438 COVID-19 outcomes, and they are driven by the same causal variant were considered to colocalize,
439 which means that the exposure and the outcome shared a single causal variant.

440

441

442 *Mendelian randomization and Colocalization with eQTL GWASs from GTEx*

443 To understand if the total gene expression levels in lung and whole blood were associated with
444 COVID-19 outcomes, without respect to the splicing or isoforms, we similarly performed MR and
445 colocalization analyses using expression quantitative trait loci (eQTLs) in lung and whole blood from
446 GTEx v.8¹⁹ (lung: N=515, of which 452 were of European ancestry, and whole blood: N=670, of which
447 570 were of European ancestry) by restricting the regions within 1 Mb of each QTL. The genetic
448 instruments were conditionally independent eQTLs for the prioritized sQTL genes in lung and/or whole
449 blood, all of which had strong support for colocalization between sQTLs and COVID-19 outcomes.

450

451 *Influence of identified sQTLs on other diseases*

452 We assessed the effects of the sQTLs which influence COVID-19 outcomes on other diseases.
453 Pleiotropic search was performed using Open Targets Genetics^{30,31} (<https://genetics.opentargets.org>)
454 and identified any GWAS lead variants that are in LD ($r^2 > 0.80$) with those sQTLs. Colocalization
455 analyses were performed using “coloc v 5.1.0.1” R package when there is available GWAS summary
456 statistics of European ancestry.

457

458 *The tissue and cell-type specific expression of the associated genes*

459 To assess the relevant tissues and cell-types for the associated gene splicing – COVID-19 outcome
460 relationships, we evaluated the associated gene expression in lung and peripheral blood mononuclear
461 cell (PBMC) of healthy controls, as well as in lung of COVID-19 patients. We first downloaded

462 consensus transcript expression levels summarized per gene in 54 tissues in Human Protein Atlas
463 (HPA)⁴¹, which was calculated as the maximum transcripts per million value (TPM) value for each
464 gene in all sub-tissues categories of each tissue, based on transcriptomics data from HPA and GTEx.
465 We also downloaded the single-cell type transcriptomic analyses, where we used all cell types in lung
466 (GSE130148⁶⁵) and peripheral blood mononuclear cell (PBMC) (GSE112845⁶⁶). We visualized RNA
467 single cell type tissue cluster data (transcript expression levels summarized per gene and cluster),
468 using \log_{10} (protein-transcripts per million [pTPM]) values with “corrplot v 0.92” R package. Lastly, we
469 obtained single-cell RNA expression profile of 23 lung COVID-19 autopsy donor tissue samples from
470 GSE171668⁴³. We calculated “pseudo-bulk” RNA expression per each cell type by taking the mean
471 value of RNA expression of the cells annotated in the same subcategory.

472

473

474 **Data availability**

475 Data from GTEx consortium (GTEx project v8¹⁹) are available from the referenced peer-reviewed
476 studies or their corresponding authors, as applicable. Summary statistics for eQTLs and sQTLs from
477 GTEx v8 are publicly available for download on the GTEx website (gtexportal.org/home/datasets).
478 Summary statistics for the COVID-19 outcomes are publicly available for download on the COVID-19
479 Host Genetics Initiative website⁶⁷ (www.covid19hg.org). The consensus transcript expression levels
480 and RNA single cell type tissue cluster data were downloadable from the Human Protein Atlas⁴¹
481 website (www.proteinatlas.org/about/download). The processed single-cell RNA expression profile of
482 23 lung COVID-19 autopsy donor tissue sample are freely available in the Gene Expression Omnibus
483 (GEO, <https://www.ncbi.nlm.nih.gov/geo/>) under accession number GSE171668⁴³.

484

485 **Code availability**

486 All code for data management and analysis is archived online at [github.com/richardslab/COVID19-](https://github.com/richardslab/COVID19-sQTLMR)
487 [sQTLMR](https://github.com/richardslab/COVID19-sQTLMR) for review and reuse.


488 **Table 1. Colocalization analyses of COVID-19 outcomes and other diseases at the identified sQTL loci.**

sQTL locus (rsID)	chr	pos (b38)	EA	NEA	intron junction	COVID-19 outcome	Other outcome	PP*
<i>ATP11A</i> (rs12585036)	13	112881427	C	T	chr13:112,875,941-112,880,546 ↑ (lung, WBC)	critical illness ↓	idiopathic pulmonary fibrosis ↑ [PMID: 31710517]	1
<i>DPP9</i> (rs12610495)	19	4717660	A	G	chr19:4,814,337-4,717,615 ↑ (lung)	critical illness ↓	idiopathic pulmonary fibrosis ↓ [PMID: 31710517]	1
<i>NPNT</i> (rs34712979)	4	105897896	A	G	chr4:105,898,001-105,927,336 ↑ (lung)	critical illness ↓	FEV1/FVC ratio ↓ [PMID: 30804560]	1
							COPD ↑ [PMID: 30804561]	-
							Asthma ↑ [PMID: 31959851]	-
<i>OAS1</i> (rs10774671)	11	112919388	G	A	chr12:112,917,700-112,919,389 ↑ (lung)	critical illness ↓	systemic lupus erythematosus ↓ [PMID: 33272962]	-
							chronic lymphocytic leukemia ↑ [PMID: 28165464]	-
<i>MUC1</i> (rs4072037)	1	155192276	C	T	chr1:155,192,310:155,192,786 ↑ (lung)	reported infection ↑	inflammatory bowel disease ↓ [PMID: 28067908]	1
							gastric cancer ↓ [PMID: 26098866]	-
							gout ↓ [PMID: 33832965]	-
							Urate level ↓ [PMID:33462484]	1


489 EA: effect allele, NEA: non-effect allele, PP: a posterior probability that there is an association for both gene expression/splicing and COVID-19 outcomes,

490 which is driven by the same causal variant. PP was only estimated when there is an available GWAS summary statistics of European ancestry.

491 **Fig. 1. Flow Diagram of Study Design**




517 **Fig. 2. MR estimates of the effect of gene splicing at *ATP11A*, *DPP9*, *NPNT*, *OAS1*, and *MUC1***
518 **with COVID-19 outcomes**






519 Forest plot showing odds ratio and 95% confidence interval from two sample Mendelian
520 Randomization analyses (two-sided). P values are unadjusted. Unit: standard deviation of intron
521 excision ratios as quantified by LeafCutter.

522 **Fig. 3. LocusZoom plots demonstrating the colocalization of the genetic determinants of mRNA**
 523 **expression, gene splicing levels and COVID-19 outcomes** LocusZoom plots of genetic signal of
 524 1MB region around each *cis*-sQTL and COVID-19 outcomes, color shows SNPs in the region in LD
 525 (r^2) to the *cis*-sQTL. (A) *ATP11A* (B) *DPP9* (C) *NPNT* (D) *MUC1*



526

527




528

529

530

531


Figure 4. The gene expression in lung and peripheral blood mononuclear cell (PBMC).



- 533 A. The consensus transcript expression levels summarized per gene in 54 tissues in Human Protein Atlas (HPA), which was calculated as the maximum
534 transcripts per million value (TPM) value for each gene in all sub-tissues categories of each tissue, based on transcriptomics data from HPA and
535 GTEX.
- 536 B. RNA single cell type tissue cluster data (transcript expression levels summarized per gene and cluster) of lung (GSE130148) and peripheral blood
537 mononuclear cell (PBMC) (GSE112845) were visualized using \log_{10} (protein-transcripts per million [pTPM]) values. Each c-X annotation is taken from
538 the clustering results performed in Human Protein Atlas.
- 539 C. Single-cell RNA expression profile of 23 lung COVID-19 autopsy donor tissue samples from GSE171668⁴³. The mean value of RNA expression of the
540 cells annotated in the same subcategory was represented as a dot per each sample. The cell type annotation was manually performed in the original
541 publication⁴³. AT1: alveolar type 1 epithelial cells, AT2: alveolar type 2 epithelial cells, EC: endothelial cells, *KRT8*⁺ PATS/ADI/DATPs: *KRT8*⁺ pre-
542 alveolar type 1 transitional cell state, MAST: mast cells, XXhi: XX (gene expression)^{high} cells, RBC: red blood cells.

543 **Extended Data Fig. 1. LocusZoom plots demonstrating the colocalization of the genetic**
 544 **determinants of mRNA expression, gene splicing levels for *OAS1* and COVID-19 outcomes.**
 545 LocusZoom plots of genetic signal of 1MB region around each *cis*-sQTL and COVID-19 outcomes,
 546 color shows SNPs in the region in LD (r^2) to the *cis*-sQTL for *OAS1*.

547




548 **Extended Data Fig. 2. The gene plots.**


549 The major gene-coding transcripts were manually curated to visualize, in relation to the sQTLs and the excised introns quantified by LeafCutter.

550 (A) *OAS1* (B) *ATP11A* (C) *DPP9* (D) *NPNT* (E) *MUC1*


A. *OAS1*




C. *DPP9*




B. *ATP11A*



D. *NPNT*



E. MUC1



551

552 **Contributions**

553 Conception and design: TN, and JBR. Formal analysis: TN. Data curation: TN, and YF. Interpretation
554 of data: TN, YF, RJA, BGG, and JBR. Funding acquisition: JBR. Investigation: TN, and YF.
555 Methodology: TN, YF, and JBR. Project administration: JBR. Resources: JBR. Supervision: YF, and
556 JBR. Validation: TN, YF, and JBR. Visualization: TN. Writing—original draft: TN. Writing—review and
557 editing: TN, YF, JW, RJA, BGG, SZ, and JBR. All authors were involved in further drafts of the
558 manuscript and revised it critically for content. All authors gave final approval of the version to be
559 published. The corresponding authors attest that all listed authors meet authorship criteria and that no
560 others meeting the criteria have been omitted. All authors were involved in further drafts of the
561 manuscript and revised it critically for content. All authors gave final approval of the version to be
562 published. The corresponding author attests that all listed authors meet authorship criteria and that no
563 others meeting the criteria have been omitted.

564

565 **Ethics declarations**

566 **Competing interests**

567 JBR's institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline and
568 Biogen for projects unrelated to this research. He is the CEO of 5 Prime Sciences
569 (www.5primesciences.com), which provides research services for biotech, pharma and venture capital
570 companies for projects unrelated to this research. No other disclosures were reported.

571

572 **Funding**

573 The Richards research group is supported by the Canadian Institutes of Health Research (CIHR)
574 (365825; 409511, 100558, 169303), the Lady Davis Institute of the Jewish General Hospital, the
575 Canada Foundation for Innovation (CFI), the NIH Foundation, Cancer Research UK, Genome
576 Québec, the Public Health Agency of Canada, the McGill Interdisciplinary Initiative in Infection and
577 Immunity and the Fonds de Recherche Québec Santé (FRQS). TN is supported by a research

578 fellowship of the Japan Society for the Promotion of Science for Young Scientists. Support from Calcul

579 Québec and Compute Canada is acknowledged.

580

581

582 **References**

- 583 1. Haas, E. J. *et al.* Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-
584 CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a
585 nationwide vaccination campaign in Israel: an observational study using national
586 surveillance data. *The Lancet* **397**, 1819–1829 (2021).
- 587 2. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N.*
588 *Engl. J. Med.* **383**, 2603–2615 (2020).
- 589 3. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. *N. Engl. J.*
590 *Med.* 1–11 (2020) doi:10.1056/nejmoa2021436.
- 591 4. Hammond, J. *et al.* Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-
592 19. *N. Engl. J. Med.* **386**, 1397–1408 (2022).
- 593 5. Huang, L. *et al.* 1-year outcomes in hospital survivors with COVID-19: a longitudinal
594 cohort study. *The Lancet* **398**, 747–758 (2021).
- 595 6. The Lancet. Understanding long COVID: a modern medical challenge. *The Lancet* **398**,
596 725 (2021).
- 597 7. Piroth, L. *et al.* Comparison of the characteristics, morbidity, and mortality of COVID-19
598 and seasonal influenza: a nationwide, population-based retrospective cohort study. *Lancet*
599 *Respir. Med.* **9**, 251–259 (2021).
- 600 8. Iacobucci, G. Covid and flu: what do the numbers tell us about morbidity and deaths?
601 *BMJ* **375**, n2514 (2021).

- 602 9. Zhou, S. *et al.* A Neanderthal OAS1 isoform protects individuals of European ancestry
603 against COVID-19 susceptibility and severity. *Nat. Med.* 1–9 (2021) doi:10.1038/s41591-
604 021-01281-1.
- 605 10. The Severe Covid-19 GWAS Group. Genomewide Association Study of Severe Covid-19
606 with Respiratory Failure. *N. Engl. J. Med.* NEJMoa2020283 (2020)
607 doi:10.1056/NEJMoa2020283.
- 608 11. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-
609 19. *Nature* 1–8 (2021) doi:10.1038/s41586-021-03767-x.
- 610 12. Pairo-Castineira, E. *et al.* Genetic mechanisms of critical illness in Covid-19. *Nature* 1–1
611 (2020) doi:10.1038/s41586-020-03065-y.
- 612 13. Kousathanas, A. *et al.* Whole genome sequencing reveals host factors underlying critical
613 Covid-19. *Nat. 2022* 1–10 (2022) doi:10.1038/s41586-022-04576-6.
- 614 14. Nakanishi, T. *et al.* Age-dependent impact of the major common genetic risk factor for
615 COVID-19 on severity and mortality. *J. Clin. Invest.* **131**, (2021).
- 616 15. Nelson, M. R. *et al.* The support of human genetic evidence for approved drug
617 indications. *Nat. Genet.* **47**, 856–860 (2015).
- 618 16. Cook, D. *et al.* Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-
619 dimensional framework. *Nat. Rev. Drug Discov.* **13**, 419–31 (2014).

- 620 17. Kornblihtt, A. R. *et al.* Alternative splicing: a pivotal step between eukaryotic
621 transcription and translation. *Nat. Rev. Mol. Cell Biol.* 2013 143 **14**, 153–165 (2013).
- 622 18. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host
623 genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *Eur. J.*
624 *Hum. Genet.* **28**, 715–718 (2020).
- 625 19. Aguet, F. *et al.* The GTEx Consortium atlas of genetic regulatory effects across human
626 tissues. *Science* (2020) doi:10.1126/SCIENCE.AAZ1776.
- 627 20. Li, Y. I. *et al.* Annotation-free quantification of RNA splicing using LeafCutter. *Nat.*
628 *Genet.* (2018) doi:10.1038/s41588-017-0004-9.
- 629 21. Ben-Eghan, C. *et al.* Don't ignore genetic data from minority populations Setting the
630 agenda in research. *ALAMY 184 Nat.* **585**, (2020).
- 631 22. Zhou, S. *et al.* A Neanderthal OAS1 isoform protects individuals of European ancestry
632 against COVID-19 susceptibility and severity. *Nat. Med.* 1–9 (2021) doi:10.1038/s41591-
633 021-01281-1.
- 634 23. Huffman, J. E. *et al.* Multi-ancestry fine mapping implicates OAS1 splicing in risk of
635 severe COVID-19. *Nat. Genet.* 2022 1–3 (2022) doi:10.1038/s41588-021-00996-8.
- 636 24. Wickenhagen, A. *et al.* A prenylated dsRNA sensor protects against severe COVID-19.
637 *Science* **374**, (2021).

- 638 25. Justa-Schuch, D., Möller, U. & Geiss-Friedlander, R. The amino terminus extension in
639 the long dipeptidyl peptidase 9 isoform contains a nuclear localization signal targeting the
640 active peptidase to the nucleus. *Cell. Mol. Life Sci. CMLS* **71**, 3611–3626 (2014).
- 641 26. Saferali, A. *et al.* Characterization of a COPD-Associated NPNT Functional Splicing
642 Genetic Variant in Human Lung Tissue via Long-Read Sequencing. *MedRxiv Prepr. Serv.*
643 *Health Sci.* 2020.10.20.20203927 (2020) doi:10.1101/2020.10.20.20203927.
- 644 27. Ng, W., Loh, A. X. W., Teixeira, A. S., Pereira, S. P. & Swallow, D. M. Genetic
645 regulation of MUC1 alternative splicing in human tissues. *Br. J. Cancer* **99**, 978–985
646 (2008).
- 647 28. Hormozdiari, F. *et al.* Colocalization of GWAS and eQTL Signals Detects Target Genes.
648 *Am. J. Hum. Genet.* **99**, 1245–1260 (2016).
- 649 29. Price, A. L., Zaitlen, N. A., Reich, D. & Patterson, N. New approaches to population
650 stratification in genome-wide association studies. *Nat. Rev. Genet.* **11**, 459 (2010).
- 651 30. Mountjoy, E. *et al.* Open targets genetics: An open approach to systematically prioritize
652 causal variants and genes at all published human GWAS trait-associated loci. *Nat. Genet.*
653 2020.09.16.299271 (2021) doi:10.1038/s41588-021-00945-5.
- 654 31. Ghousaini, M. *et al.* Open Targets Genetics: Systematic identification of trait-associated
655 genes using large-scale genetics and functional genomics. *Nucleic Acids Res.* **49**, D1311–
656 D1320 (2021).

- 657 32. Allen, R. J. *et al.* Genome-Wide Association Study of Susceptibility to Idiopathic
658 Pulmonary Fibrosis. *Am. J. Respir. Crit. Care Med.* **201**, 564–574 (2020).
- 659 33. Shrine, N. *et al.* New genetic signals for lung function highlight pathways and chronic
660 obstructive pulmonary disease associations across multiple ancestries. *Nat. Genet.* **51**,
661 481–493 (2019).
- 662 34. Sakornsakolpat, P. *et al.* Genetic landscape of chronic obstructive pulmonary disease
663 identifies heterogeneous cell-type and phenotype associations. *Nat. Genet.* **51**, 494–505
664 (2019).
- 665 35. Olafsdottir, T. A. *et al.* Eighty-eight variants highlight the role of T cell regulation and
666 airway remodeling in asthma pathogenesis. *Nat. Commun.* **11**, 393 (2020).
- 667 36. Yin, X. *et al.* Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for
668 systemic lupus erythematosus. *Ann. Rheum. Dis.* **80**, 632–640 (2021).
- 669 37. Law, P. J. *et al.* Genome-wide association analysis implicates dysregulation of immunity
670 genes in chronic lymphocytic leukaemia. *Nat. Commun.* **8**, 14175 (2017).
- 671 38. Helgason, H. *et al.* Loss-of-function variants in ATM confer risk of gastric cancer. *Nat.*
672 *Genet.* **47**, 906–910 (2015).
- 673 39. Sandoval-Plata, G., Morgan, K. & Abhishek, A. Variants in urate transporters, ADH1B,
674 GCKR and MEPE genes associate with transition from asymptomatic hyperuricaemia to

- 675 gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians
676 using data from the UK Biobank. *Ann. Rheum. Dis.* **80**, 1220–1226 (2021).
- 677 40. De Lange, K. M. *et al.* Genome-wide association study implicates immune activation of
678 multiple integrin genes in inflammatory bowel disease. *Nat. Genet.* (2017)
679 doi:10.1038/ng.3760.
- 680 41. Karlsson, M. *et al.* A single-cell type transcriptomics map of human tissues. *Sci. Adv.* **7**,
681 eabh2169 (2021).
- 682 42. Castranova, V., Rabovsky, J., Tucker, J. H. & Miles, P. R. The alveolar type II epithelial
683 cell: a multifunctional pneumocyte. *Toxicol. Appl. Pharmacol.* **93**, 472–483 (1988).
- 684 43. Delorey, T. M. *et al.* COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular
685 targets. *Nature* **595**, 107–113 (2021).
- 686 44. Katzourakis, A. COVID-19: endemic doesn't mean harmless. *Nature* **601**, 485 (2022).
- 687 45. Levin, A. A. Treating Disease at the RNA Level with Oligonucleotides. *N. Engl. J. Med.*
688 **380**, 57–70 (2019).
- 689 46. Kole, R., Krainer, A. R. & Altman, S. RNA therapeutics: beyond RNA interference and
690 antisense oligonucleotides. *Nat. Rev. Drug Discov.* **11**, 125–140 (2012).
- 691 47. Davis, M. E. *et al.* Evidence of RNAi in humans from systemically administered siRNA
692 via targeted nanoparticles. *Nature* **464**, 1067–1070 (2010).

- 693 48. Segawa, K. *et al.* A sublethal ATP11A mutation associated with neurological
694 deterioration causes aberrant phosphatidylcholine flipping in plasma membranes. *J. Clin.*
695 *Invest.* **131**, 148005 (2021).
- 696 49. Barkauskas, C. E. *et al.* Type 2 alveolar cells are stem cells in adult lung. *J. Clin. Invest.*
697 **123**, 3025–3036 (2013).
- 698 50. Královičová, J. & Vořechovský, I. Position-Dependent Repression and Promotion of
699 *DQBI* Intron 3 Splicing by GGGG Motifs. *J. Immunol.* **176**, 2381–2388 (2006).
- 700 51. Hollingsworth, L. R. *et al.* DPP9 sequesters the C terminus of NLRP1 to repress
701 inflammasome activation. *Nature* **592**, 778–783 (2021).
- 702 52. Sefik, E. *et al.* Inflammasome activation in infected macrophages drives COVID-19
703 pathology. *Nature* **606**, 585–593 (2022).
- 704 53. Ishikawa, N., Hattori, N., Yokoyama, A. & Kohno, N. Utility of KL-6/MUC1 in the
705 clinical management of interstitial lung diseases. *Respir. Investig.* **50**, 3–13 (2012).
- 706 54. Fowler, J. C., Teixeira, A. S., Vinall, L. E. & Swallow, D. M. Hypervariability of the
707 membrane-associated mucin and cancer marker MUC1. *Hum. Genet.* **113**, 473–479
708 (2003).
- 709 55. Mukamel, R. E. *et al.* Protein-coding repeat polymorphisms strongly shape diverse human
710 phenotypes. *Science* **373**, 1499–1505 (2021).

- 711 56. Saeki, N. *et al.* A functional single nucleotide polymorphism in mucin 1, at chromosome
712 1q22, determines susceptibility to diffuse-type gastric cancer. *Gastroenterology* **140**, 892–
713 902 (2011).
- 714 57. Logsdon, G. A., Vollger, M. R. & Eichler, E. E. Long-read human genome sequencing
715 and its applications. *Nat. Rev. Genet.* **21**, 597–614 (2020).
- 716 58. Kraemer, S. *et al.* From SOMAmer-based biomarker discovery to diagnostic and clinical
717 applications: A SOMAmer-based, streamlined multiplex proteomic assay. *PLoS ONE* **6**,
718 (2011).
- 719 59. Rotival, M., Quach, H. & Quintana-Murci, L. Defining the genetic and evolutionary
720 architecture of alternative splicing in response to infection. *Nat. Commun.* **10**, 1671
721 (2019).
- 722 60. Allen, R. J. *et al.* Genetic overlap between idiopathic pulmonary fibrosis and COVID-19.
723 *Eur. Respir. J.* **60**, 2103132 (2022).
- 724 61. Võsa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic
725 loci and polygenic scores that regulate blood gene expression. *Nat. Genet.* **53**, 1300–1310
726 (2021).
- 727 62. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the
728 human phenome. *eLife* **7**, e34408 (2018).

- 729 63. Burgess, S., Davies, N. M. & Thompson, S. G. Bias due to participant overlap in two-
730 sample Mendelian randomization. *Genet. Epidemiol.* **40**, 597–608 (2016).
- 731 64. Burgess, S., Thompson, S. G., & CRP CHD Genetics Collaboration. Avoiding bias from
732 weak instruments in Mendelian randomization studies. *Int. J. Epidemiol.* **40**, 755–764
733 (2011).
- 734 65. Vieira Braga, F. A. *et al.* A cellular census of human lungs identifies novel cell states in
735 health and in asthma. *Nat. Med.* **25**, 1153–1163 (2019).
- 736 66. Chen, J. *et al.* PBMC fixation and processing for Chromium single-cell RNA sequencing.
737 *J. Transl. Med.* **16**, 198 (2018).
- 738 67. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-
739 19. *Nature* **600**, 472–477 (2021).
- 740